Format

Send to

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2006 Dec;113(12):2276-80. Epub 2006 Sep 25.

The International Classification of Retinoblastoma predicts chemoreduction success.

Author information

1
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

Abstract

PURPOSE:

To evaluate the reliability of the International Classification of Retinoblastoma (ICRB) for predicting treatment success with chemoreduction (CRD).

DESIGN:

Noncomparative interventional case series.

PARTICIPANTS:

Two hundred forty-nine consecutive eyes.

METHODS:

All eyes were treated with CRD and were classified according to the ICRB: group A included those eyes with retinoblastoma </=3 mm; group B included those eyes with retinoblastoma >3 mm, macular location, or minor subretinal fluid; group C included those eyes with retinoblastoma with localized seeds; group D included those eyes with retinoblastoma with diffuse seeds; group E included those eyes with massive retinoblastoma necessitating enucleation. The CRD regimen included vincristine, etoposide, and carboplatin for 6 cycles plus local consolidation with thermotherapy or cryotherapy.

MAIN OUTCOME MEASURE:

Chemoreduction success, defined as avoidance of external beam radiotherapy or enucleation.

RESULTS:

Of the 249 eyes, 23 (9%) were in group A, 96 (39%) were in group B, 21 (8%) were in group C, and 109 (44%) were in group D. In this series, group E eyes were managed with enucleation. Treatment success was achieved in 100% of group A, 93% of group B, 90% of group C, and 47% of group D eyes.

CONCLUSIONS:

The ICRB can be of assistance in predicting CRD success for retinoblastoma. Additional treatment methods are necessary to salvage more group D eyes.

PMID:
16996605
DOI:
10.1016/j.ophtha.2006.06.018
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center